The decreased in GFR or albuminuria has been associated with the presence of nonalcoholic steatohepatitis or the severity of fibrosis, whereas improvement in liver histology is associated with improvement in CKD.75 arGLP1 improves insulin levels, regulates autophagy, inhibits hepatic neoglycogenesis, reduces hepatic fat content, plasma liver enzyme levels and hepatic histological improvements have been described with liraglutide and semaglutide.49,76 Likewise, epicardial and perirenal fat are associated with increased cardiorenal risk,77 so that the reduction in ectopic fat43 as demonstrated with the use of arGLP-1 has could be beneficial in CKD
Department of Health and Human Services (2026)
Comparing Semaglutide and Tirzepatide While both semaglutide and tirzepatide are effective in managing obesity and type 2 diabetes, their mechanisms of action differ slightly: Semaglutide is a GLP-1 receptor agonist that primarily works by: - Slowing gastric emptying - Reducing appetite through brain signaling - Stimulating insulin release from the pancreas - Decreasing glucagon secretion Tirzepatide, on the other hand, is a dual GIP and GLP-1 receptor agonist, often referred to as a "twincretin"[8]
The salt forms are different active ingredients than are used in the approved drugs